Guardant Health Inc (GH) Opciones

GH buy the dip

GH that awful Cathie has been a recent buyer

I'm in, $33 ish I like the potential. Short wise only 6% of float and 6 million shares only 200 million so I don't think we'll see a squeeze like ASTS has been doing.

X. I just like to throw down a marker when I invest, I'm a long as in 80% of the time I hold shares for years and years many for decades.

The American biotechnology company Guardant Health, which produces liquid biopsy tests to detect cancer from mutations and other modifications in blood samples,[1] was co-founded by Helmy Eltoukhy and AmirAli Talasaz during 2012–2013.[2][3] According to John Dorfman of the Pittsburgh Tribune-Review, Talasaz and Eltoukhy discovered a technique which "involves detecting and monitoring tumor fragments circulating in the patient's bloodstream", as an alternative to traditional tissue biopsies.[4] The duo met at Stanford University in 2002 and worked together at Illumina, until Talasaz left in 2012.[5]

I would add GH with EXAS both would score on the final outcome. FDA is expected to decide whether to approve Shield later this year.

For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook. $GH

$GH -Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer.

Guardant Health unveiled initial results from the ECLIPSE study validating the performance of the Shield test at the 2023 DDW meeting. The data served as the basis for Guardant Health’s submission of a premarket approval (PMA) application to the FDA, and the full study results have since been published in the March 2024 issue of The New England Journal of Medicine. An FDA Advisory Panel is scheduled to review the PMA application on May 23.

The full abstracts for Guardant Health and a list of all abstracts being presented at the meeting will be available at the DDW website.

For information and updates from the meeting, follow Guardant Health on LinkedIn, X (Twitter) and Facebook. $GH

$GH Guardant Health Inc NASDAQ -Guardant Health to present real-world data supporting performance of Shield™ blood test for colorectal cancer screening at 2024 Digestive Disease Week
May 16 2024 - 8:05AM


Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will present data from two real-world studies at the 2024 Digestive Disease Week (DDW) meeting in Washington, DC, highlighting the value of the company’s Shield™ test in colorectal cancer (CRC) screening.

“One in three eligible American adults have not been screened for CRC, in part because the currently available methods are unpleasant or inconvenient,” said AmirAli Talasaz, co-CEO of Guardant Health. “The data we will share at DDW underscores the important role that our Shield blood test can have in both improving screening rates and in detecting more colorectal cancer at an early stage, when it is most treatable. We look forward to sharing this important data at DDW.”

GH—(-34%/AH)—reports_results_of “Shield” ctDNA—(liquid biopsy)—diagnostic_for colorectal cancer:

https://finance.yahoo.com/news/guardant-health-announces-positive-results-211600504.html

https://finance.yahoo.com/news/1-guardant-dna-blood-test-220041937.html

GH’s data aren’t bad, but they aren’t as good as those for EXAS’s Cologuard, which is based on a stool sample rather than a blood sample.

EXAS is +24%/AH, adding about $2B(!) to its market cap.

In #msg-168735158 (from May 2022), I said: Although GH says Shield is as good as EXAS’ Cologuard and MYNZ’s ColoAlert, I find it hard to believe that a blood test can be as sensitive for CRC (and precancerous lesions) as a stool-based test.I stand by that.

I'm still feeling very good about owning this stock. There is no way I'll sell this before the next five years.

I like the nice, gradual, consistent rise in the share price. I think there is no way to lose money here, and I think the gains will be very substantial over the next two to three years.

So am I. This is THE company I have chosen in which to put my investment dollars that I feel is both a high-growth situation and one in which I am certain not to lose money.

2-3 years I'm thinking this is @ 3-5X current share price